Zoetis Inc. (NYSE:ZTS) Position Lifted by Renaissance Investment Group LLC

Renaissance Investment Group LLC raised its stake in shares of Zoetis Inc. (NYSE:ZTS) by 1.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 49,400 shares of the company’s stock after acquiring an additional 834 shares during the quarter. Zoetis makes up 2.4% of Renaissance Investment Group LLC’s portfolio, making the stock its 18th biggest position. Renaissance Investment Group LLC’s holdings in Zoetis were worth $9,750,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in ZTS. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its position in shares of Zoetis by 430.8% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock worth $26,000 after buying an additional 112 shares during the last quarter. VitalStone Financial LLC acquired a new stake in shares of Zoetis in the 1st quarter worth about $37,000. Evermay Wealth Management LLC increased its holdings in shares of Zoetis by 439.3% in the 1st quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock worth $25,000 after acquiring an additional 123 shares during the period. Worth Asset Management LLC acquired a new stake in shares of Zoetis in the 1st quarter worth about $26,000. Finally, VisionPoint Advisory Group LLC acquired a new stake in shares of Zoetis in the 2nd quarter worth about $29,000. 89.47% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 363 shares of Zoetis stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $197.74, for a total value of $71,779.62. Following the transaction, the executive vice president now owns 20,417 shares of the company’s stock, valued at $4,037,257.58. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.12% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on ZTS. The Goldman Sachs Group increased their price objective on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Piper Sandler raised their target price on shares of Zoetis from $215.00 to $220.00 and gave the company an “overweight” rating in a research note on Tuesday, February 20th. StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Barclays raised their target price on shares of Zoetis from $255.00 to $260.00 and gave the company an “overweight” rating in a research note on Wednesday, February 14th. Finally, Stifel Nicolaus raised their target price on shares of Zoetis from $195.00 to $215.00 and gave the company a “buy” rating in a research note on Friday, January 12th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $224.33.

Zoetis Trading Down 0.8 %

Shares of ZTS traded down $1.31 during midday trading on Friday, hitting $172.57. The stock had a trading volume of 3,399,667 shares, compared to its average volume of 2,577,704. Zoetis Inc. has a fifty-two week low of $151.03 and a fifty-two week high of $201.92. The business has a 50-day simple moving average of $190.23 and a two-hundred day simple moving average of $183.46. The firm has a market cap of $79.01 billion, a P/E ratio of 34.04, a price-to-earnings-growth ratio of 2.69 and a beta of 0.87. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). The firm had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The business’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.15 earnings per share. As a group, equities analysts forecast that Zoetis Inc. will post 5.8 EPS for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be paid a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a yield of 1.00%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s dividend payout ratio (DPR) is presently 34.12%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.